Article Sidebar

PDF
Date Published: 22/01/2024
Abstract Views: 95
Views PDF: 79
DOI: https://doi.org/10.56535/jmpm.v49i1.548
Issue
Vol. 49 No. 1 (2024): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 1 - 2024
Section
Articles
How to Cite
Ngoc Pham, D., Quang Dang, V., Khanh Pham, H., Cao Hồng, P., & Thi Nghiem, M. C. (2024). RESEARCH ON THE PROGNOSTIC VALUE OF NLR, PLR INDEX IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA. Journal of Military Pharmaco-medicine, 49(1), 17-25. https://doi.org/10.56535/jmpm.v49i1.548

RESEARCH ON THE PROGNOSTIC VALUE OF NLR, PLR INDEX IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Pham Ngoc Diep , Dang Quang Vinh, Pham Khanh Hung, Phúc Cao Hồng, Nghiem Thi Minh Chau

Main Article Content

Abstract

Objectives: To determine the prognostic treatment value of NLR and PLR indexes in esophageal squamous cell carcinoma. Methods: A retrospective descriptive study on 42 squamous cell esophageal cancer patients. All patients were treated with chemoradiation therapy. The dose radiation was 41,4Gy pre- operation, 50,4Gy (post operation), chemotherapy with paclitaxel 50 mg/m2, and carboplatin AUC 2. Results: The cutoff values of NLR and PLR were 4.37; 240, alternatively. Patients whose NLR index was over 4.37 and PLR index was over 240 had poor prognosis (p < 0.0001). Conclusion: NLR and PLR index can be valued treatment prognostic indexes in esophageal squamous cell carcinoma.

Article Details

Keywords

NLR, PLR, Esophageal cancer, Squamous cell carcinoma

References

1. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209-249.
2. Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg. 2018; 41:210-215.
3. Vincent Y, Rosenberg SA Devita, Hellman and Rosenberg's cancer principles and practise of oncology 11 edition. Walters Kluwer. 2019; 4361.
4. Ethier JL, Desautels D, Templeton A et al. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: A systematic review and meta-analysis. Breast Cancer Res. 2017; 19:2.
5. Tong YS, Tan J, Zhou XL et al. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017; 15:221.
6. Chen JH, Zhai ET, Yuan YJ et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017; 23:6261-6272.
7. Nguyễn Thị Hà. Kết quả hóa xạ trị đồng thời tiền phẫu ung thư thực quản 1/3 giữa - dưới giai đoạn II, III tại Bệnh viện Trung ương Quân đội 108. Luận văn thạc sỹ y học. 2021.
8. Ishibashi Y, Tsujimoto H, Hiraki S et al. Prognostic value of preoperative systemic immunoinflammatory measures in patients with esophageal cancer. Ann Surg Oncol. 2018; 25:3288-3299.
9. Sun Y , Zhang L. The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: Evidence from a meta- analysis. Cancer Manag Res. 2018; 10:6167-6179.
10. Zhu S, Miao CW, Wang ZT et al. Sensitivity value of hematological markers in patients receiving chemoradiotherapy for esophageal squamous cell carcinoma. Onco Targets Ther. 2016; 9:6187-6193.
11. Zheng Z, Yang C, Cai C et al. The preoperative neutrophil lymphocyte ratio and platelet lymphocyte ratio predicts disease-free survival in resectable esophageal squamous cell carcinoma. Cancer Manag Res. 2021; 13:7511-7516.